{"id":"W4389606368","doi":"10.1016/s1470-2045(23)00540-5","title":"Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"ca_institutions":"Roche (Canada)","funders":"National Health and Medical Research Council; F. Hoffmann-La Roche; Roche","keywords":"Metastatic Urothelial Carcinoma; Atezolizumab; Medicine; Chemotherapy; Placebo; Oncology; Internal medicine; Urothelial carcinoma; Carcinoma; Urology; Cancer; Bladder cancer; Immunotherapy; Pathology; Pembrolizumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002447834,0.001558526,0.003883974,0.0004561254,0.0002756394,0.0009772088,0.001005131,0.001645489,0.003883353],"category_scores_gemma":[0.00187866,0.0005529696,0.004034441,0.000478786,0.001153821,0.001080882,0.0005170566,0.003523717,0.0005612104],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008049407,"about_ca_system_score_gemma":0.0007908383,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001091667,"about_ca_topic_score_gemma":0.002281985,"domain_scores_codex":[0.999119,0.0005821043,0.00004029474,0.0001111861,0.00004372755,0.0001036967],"domain_scores_gemma":[0.9988295,0.0004952296,0.0002606665,0.00009521539,0.00004547836,0.0002739405],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9784709,0.002370902,0.0003694614,0.0006056208,0.001156014,0.00001774415,0.0000405098,0.0004541287,0.001686936,0.0000578679,0.0004034933,0.01436643],"study_design_scores_gemma":[0.8776712,0.1168515,0.002844334,0.0000503334,0.001241891,0.00002694551,0.0000286659,0.0004302188,0.0003296715,0.0001269243,0.0003790772,0.00001907268],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9877284,0.007406757,0.0005781347,0.0005645551,0.0004937624,0.001007652,0.0009151931,0.0001085088,0.001197133],"genre_scores_gemma":[0.9895049,0.003557025,0.001022312,0.0007924577,0.0003737956,0.001173237,0.001051953,0.00004346268,0.002480807],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003883974,"threshold_uncertainty_score":0.01299113,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0867280660593854,"score_gpt":0.389108017368519,"score_spread":0.3023799513091336,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}